Beth Israel Deaconess Medical Center
Boston, MA
Accepting patients
CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
- CAR T Cell
- CELMoD
- GPRC5D
- Phase 1
Accepting patients
Daratumumab Combination Therapy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
- Monoclonal Antibody
- Proteasome Inhibitor
- CD38
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Not yet accepting
Elranatamab as Consolidation
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- CD3
- Phase 2
Not yet accepting
Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
- Monoclonal Antibody
- SLAMF7
- Phase 1/2
Accepting patients
Investigational Cord Blood Units
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
- Allogeneic Stem Cell Transplant
- Cord Blood
- Phase 2
Accepting patients
Horizon Adaptive Platform
MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
- BCMA
- CD3
- Randomization
- Phase 2
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Not yet accepting
Dendritic Cell / Multiple Myeloma Fusion Vaccine
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
- Vaccine
- Phase 1
Not currently accepting
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- BCMA
- Phase 3
1 hidden based on your filters. Show All